Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06901232 · ClinicalTrials.gov registry record · NA

Mindfulness-based Neurofeedback to Reduce Negative Thinking in CHARMS Adolescents

A NA study, sponsored by Massachusetts General Hospital.

Not yet
Registry status
NA
Development phase
90
Enrollment target

NCT06901232: Clinical Trial NA study, sponsored by Massachusetts General Hospital.

NCT06901232 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06901232, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.

NOT YET RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target

Study Summary

The study will test the hypothesis that mindfulness-based neurofeedback (mbNF) will improve repetitive negative thinking and social and role functioning over sham neurofeedback in adolescents at risk for serious mental illness. To do so, 90 adolescents ages 14-21 with elevated repetitive negative thinking will be enrolled into a double-blind randomized clinical trial of sessions of mindfulness training with either active mindfulness-based neurofeedback or sham neurofeedback and three months of mindfulness practice and follow up.

Interventions

  • BEHAVIORAL Mindfulness Training
  • BEHAVIORAL Active mindfulness-based neurofeedback (Active mbNF)
  • BEHAVIORAL Sham mindfulness-based neurofeedback

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2027-09
Est. Completion 2029-04
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT06901232

The ClinicalTrials.gov registry entry for NCT06901232 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Mindfulness Training is the first listed.

NCT06901232 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06901232 about?

NCT06901232 is a clinical study titled "Mindfulness-based Neurofeedback to Reduce Negative Thinking in CHARMS Adolescents". The study will test the hypothesis that mindfulness-based neurofeedback (mbNF) will improve repetitive negative thinking and social and role functioning over sham neurofeedback in adolescents at risk for serious mental illness. To do so, 90 adolescents ages 14-21 with elevated repetitive negative th...

What is the current status of trial NCT06901232?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2027-09. Estimated completion is 2029-04.

What interventions are being tested in trial NCT06901232?

The interventions under investigation include: Mindfulness Training (BEHAVIORAL), Active mindfulness-based neurofeedback (Active mbNF) (BEHAVIORAL), Sham mindfulness-based neurofeedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT06901232?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.